The effectiveness of CDK7 inhibition has been demonstrated in various aggressive cancer types, including small-cell lung cancer [20], triple-negative breast cancer (TNBC) [21], MYCN-amplified neuroblastoma [47], osteosarcoma [173] and pancreatic ductal adenocarcinoma [174]. Here, MYCN is linked to cancer.